JP2022551081A5 - - Google Patents
Info
- Publication number
- JP2022551081A5 JP2022551081A5 JP2022520371A JP2022520371A JP2022551081A5 JP 2022551081 A5 JP2022551081 A5 JP 2022551081A5 JP 2022520371 A JP2022520371 A JP 2022520371A JP 2022520371 A JP2022520371 A JP 2022520371A JP 2022551081 A5 JP2022551081 A5 JP 2022551081A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023194494A JP7809680B2 (ja) | 2019-10-02 | 2023-11-15 | 癌処置のための多重特異性結合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19201200.3 | 2019-10-02 | ||
| EP19201200 | 2019-10-02 | ||
| PCT/EP2020/077586 WO2021064137A2 (en) | 2019-10-02 | 2020-10-01 | Multi-specific binding proteins for cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023194494A Division JP7809680B2 (ja) | 2019-10-02 | 2023-11-15 | 癌処置のための多重特異性結合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551081A JP2022551081A (ja) | 2022-12-07 |
| JP2022551081A5 true JP2022551081A5 (enExample) | 2022-12-27 |
| JP7387885B2 JP7387885B2 (ja) | 2023-11-28 |
Family
ID=68136317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520371A Active JP7387885B2 (ja) | 2019-10-02 | 2020-10-01 | 癌処置のための多重特異性結合タンパク質 |
| JP2023194494A Active JP7809680B2 (ja) | 2019-10-02 | 2023-11-15 | 癌処置のための多重特異性結合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023194494A Active JP7809680B2 (ja) | 2019-10-02 | 2023-11-15 | 癌処置のための多重特異性結合タンパク質 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11732045B2 (enExample) |
| EP (1) | EP4038100A2 (enExample) |
| JP (2) | JP7387885B2 (enExample) |
| KR (1) | KR20220075383A (enExample) |
| CN (4) | CN122103354A (enExample) |
| AR (1) | AR120138A1 (enExample) |
| AU (1) | AU2020358893A1 (enExample) |
| BR (1) | BR112022004047A2 (enExample) |
| CA (1) | CA3153372A1 (enExample) |
| CL (1) | CL2022000664A1 (enExample) |
| CO (1) | CO2022003552A2 (enExample) |
| CR (1) | CR20220136A (enExample) |
| DO (1) | DOP2022000060A (enExample) |
| EC (1) | ECSP22019193A (enExample) |
| IL (1) | IL291817A (enExample) |
| JO (1) | JOP20220079A1 (enExample) |
| MX (1) | MX2022004042A (enExample) |
| MY (1) | MY209387A (enExample) |
| PE (1) | PE20221412A1 (enExample) |
| PH (1) | PH12022550693A1 (enExample) |
| SA (1) | SA522432139B1 (enExample) |
| TW (1) | TWI878355B (enExample) |
| UA (1) | UA130106C2 (enExample) |
| WO (1) | WO2021064137A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023504675A (ja) | 2020-05-19 | 2023-02-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ガンの処置のための結合分子 |
| CN117321087A (zh) | 2021-03-26 | 2023-12-29 | 先天制药公司 | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| CN117616050A (zh) | 2021-06-09 | 2024-02-27 | 先天制药公司 | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| CN114395045B (zh) * | 2021-12-07 | 2023-06-09 | 合肥天港免疫药物有限公司 | B7h6抗体及其应用 |
| CN114395047B (zh) * | 2021-12-07 | 2023-11-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| CN114395043B (zh) * | 2021-12-07 | 2023-07-11 | 合肥天港免疫药物有限公司 | Ncr3lg1抗体及其应用 |
| US20240174642A1 (en) | 2022-10-26 | 2024-05-30 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| WO2024088991A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| AU2023370123A1 (en) | 2022-10-26 | 2025-04-17 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731A (en) | 1848-08-22 | Elisha k | ||
| US168A (en) | 1837-04-17 | Improvement in fire-arms | ||
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| WO1994003678A1 (en) | 1992-08-10 | 1994-02-17 | Alcan Aluminium Uk Limited | Fence |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| EP1361892A4 (en) | 2001-01-17 | 2004-10-13 | Trubion Pharmaceuticals Inc | BINDING DOMAIN FUSION PROTEIN Immunoglobulin |
| EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| NL1019562C2 (nl) | 2001-12-13 | 2003-06-17 | Heineken Tech Services | Klepsamenstel voor gebruik bij drankafgifte. |
| US8764654B2 (en) | 2008-03-19 | 2014-07-01 | Zin Technologies, Inc. | Data acquisition for modular biometric monitoring system |
| US8236308B2 (en) * | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| CN101287764B (zh) | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| US7858759B2 (en) | 2007-10-04 | 2010-12-28 | Zymogenetics, Inc. | Anti-zB7H6 antibody-drug conjugates |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| FI20090280L (fi) | 2009-07-17 | 2011-01-18 | Kone Corp | Hissijärjestely ja menetelmä hissikorin liikuttamiseksi hissikuilussa |
| CA2777527C (en) | 2009-12-23 | 2020-06-23 | Esbatech, An Alcon Biomedical Research Unit Llc | Method for decreasing immunogenicity |
| WO2012162067A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| MY167125A (en) | 2011-08-17 | 2018-08-13 | Glaxo Group Ltd | Modified proteins and peptides |
| DK2766392T3 (da) * | 2011-10-10 | 2019-10-07 | Xencor Inc | Fremgangsmåde til oprensning af antistoffer |
| CN104395344B (zh) * | 2012-05-07 | 2019-08-13 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
| CN104640561A (zh) * | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| CN114634569B (zh) * | 2016-04-15 | 2024-08-20 | 达特茅斯大学理事会 | 高亲和力b7-h6抗体和抗体片段 |
| EP3848393A1 (en) | 2016-05-18 | 2021-07-14 | Boehringer Ingelheim International GmbH | Antibody molecules for cancer treatment |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
-
2020
- 2020-09-30 TW TW109134076A patent/TWI878355B/zh active
- 2020-10-01 CN CN202511886140.8A patent/CN122103354A/zh active Pending
- 2020-10-01 CN CN202511907124.2A patent/CN122277744A/zh active Pending
- 2020-10-01 CR CR20220136A patent/CR20220136A/es unknown
- 2020-10-01 PE PE2022000468A patent/PE20221412A1/es unknown
- 2020-10-01 CN CN202080068909.4A patent/CN114641496B/zh active Active
- 2020-10-01 CN CN202511896772.2A patent/CN122080223A/zh active Pending
- 2020-10-01 AR ARP200102733A patent/AR120138A1/es unknown
- 2020-10-01 IL IL291817A patent/IL291817A/en unknown
- 2020-10-01 AU AU2020358893A patent/AU2020358893A1/en active Pending
- 2020-10-01 MY MYPI2022001742A patent/MY209387A/en unknown
- 2020-10-01 UA UAA202201295A patent/UA130106C2/uk unknown
- 2020-10-01 US US17/060,111 patent/US11732045B2/en active Active
- 2020-10-01 MX MX2022004042A patent/MX2022004042A/es unknown
- 2020-10-01 WO PCT/EP2020/077586 patent/WO2021064137A2/en not_active Ceased
- 2020-10-01 CA CA3153372A patent/CA3153372A1/en active Pending
- 2020-10-01 JP JP2022520371A patent/JP7387885B2/ja active Active
- 2020-10-01 PH PH1/2022/550693A patent/PH12022550693A1/en unknown
- 2020-10-01 EP EP20789508.7A patent/EP4038100A2/en active Pending
- 2020-10-01 BR BR112022004047A patent/BR112022004047A2/pt unknown
- 2020-10-01 KR KR1020227014608A patent/KR20220075383A/ko active Pending
-
2022
- 2022-01-31 JO JOP/2022/0079A patent/JOP20220079A1/ar unknown
- 2022-03-14 EC ECSENADI202219193A patent/ECSP22019193A/es unknown
- 2022-03-18 DO DO2022000060A patent/DOP2022000060A/es unknown
- 2022-03-18 CL CL2022000664A patent/CL2022000664A1/es unknown
- 2022-03-25 CO CONC2022/0003552A patent/CO2022003552A2/es unknown
- 2022-03-31 SA SA522432139A patent/SA522432139B1/ar unknown
-
2023
- 2023-06-20 US US18/337,693 patent/US20230340130A1/en active Pending
- 2023-11-15 JP JP2023194494A patent/JP7809680B2/ja active Active